menu
    • menu
    [{"orgOrder":0,"company":"Aurigene","sponsor":"Curis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Aurigene Discovery Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Aurigene \/ Aurigene Discovery Technologies"},{"orgOrder":0,"company":"Aurigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AUR101","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Not Applicable"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AUR102","moa":"CDK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/ Aurigene"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"XL102","moa":"CDK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"CBM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0.44,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"","sponsorNew":"Aurigene \/ Olema","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ Olema"},{"orgOrder":0,"company":"Aurigene","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aurigene \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ EQRx"},{"orgOrder":0,"company":"Aurigene","sponsor":"Curis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene \/ Aurigene"},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OP-3136","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aurigene \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/ Aurigene"}]

    Find Clinical Drug Pipeline Developments & Deals by Aurigene

    Menu

    Aurigene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OP-3136

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Olema Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Olema Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as Development Candidate

                            Details : OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor. It is discovered and selected as a lead candidate for the treatment of breast cancer.

                            Brand Name : OP-3136

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 08, 2024

                            Lead Product(s) : OP-3136

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Olema Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Curis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

                            Details : With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of...

                            Brand Name : CA-4948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2023

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Curis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnershi...

                            Details : Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Olema Oncology

                            Deal Size : $438.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Nov...

                            Details : Under the terms of the agreement, Olema and Aurigene will jointly direct preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $8.0 million

                            June 09, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Olema Oncology

                            Deal Size : $438.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XL114

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Exelixis

                            Deal Size : $22.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New...

                            Details : In preclinical development, XL114 also demonstrated a high degree of selectivity against a broad safety pharmacology panel of enzymes and receptors.

                            Brand Name : AUR104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 14, 2021

                            Lead Product(s) : XL114

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Exelixis

                            Deal Size : $22.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XL102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $29.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exelixis In-Licenses Aurigene’s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Tr...

                            Details : Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the comp...

                            Brand Name : XL102

                            Molecule Type : Small molecule

                            Upfront Cash : $10.0 million

                            December 07, 2020

                            Lead Product(s) : XL102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $29.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUR102

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Exelixis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exelixis and Aurigene Announce Promising Preclinical Data to Be Presented at the ENA Symposium Back Developmen...

                            Details : Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies.

                            Brand Name : AUR102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 09, 2020

                            Lead Product(s) : AUR102

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Exelixis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUR101

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurigene announces dose administration in first patient study for phase II study of psoriasis

                            Details : The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 18, 2020

                            Lead Product(s) : AUR101

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aurigene

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-Aminopyrrolidine dihydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Curis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Curis and Aurigene Announce Amendment of Collaboration

                            Details : Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer. Curis retains U.S., E.U., and rest of world rights to CA-170.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : 3-Aminopyrrolidine dihydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Curis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth